Rheumatology International

, Volume 31, Issue 4, pp 451–456

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

  • Shin-ya Kawashiri
  • Atsushi Kawakami
  • Satoshi Yamasaki
  • Takahiro Imazato
  • Naoki Iwamoto
  • Keita Fujikawa
  • Toshiyuki Aramaki
  • Mami Tamai
  • Hideki Nakamura
  • Hiroaki Ida
  • Tomoki Origuchi
  • Yukitaka Ueki
  • Katsumi Eguchi
Original Article

Abstract

We investigated the effects of anti-IL-6 receptor antibody, tocilizumab (TCZ), on lipid metabolism. Nineteen patients with rheumatoid arthritis (RA), entered in clinical case–control study of SAMURAI trial at Sasebo Chuo Hospital, were examined. Nine patients received TCZ monotherapy at 8 mg/kg intravenously every 4 weeks (TCZ group) and 10 patients received conventional DMARDs (control group). Serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), apolipoprotein (Apo) A-1, Apo A-2 and Apo B as well as disease activity score (DAS), C-reactive protein and serum amyloid A protein were examined at baseline and after 3 months of the treatment. IL-6 inversely was correlated with LDL, Apo A-1 and Apo A-2, and also tended to correlate with Apo B. In TCZ group, serum levels of TC, HDL, LDL, Apo A-1 and Apo A-2 were significantly increased after 3 months treatment with TCZ. There was no significant change in Apo B, the atherogenic index, and TC/HDL by the TCZ treatment. Changes in the DAS28-ESR negatively correlated with those in TC. In one patient, whose serum level of TCZ was not detected after 3 months of the treatment, the absence of the increment in serum levels of Apo A-1 and A-2 in the patient was remarkable. All of the markers did not change during 3 months in control group. These data may raise an important issue to evaluate the impact of these alternations in lipid metabolism for longer periods in RA patients treated with TCZ.

Keywords

Apolipoprotein Cholesterol Tocilizumab Rheumatoid arthritis 

Abbreviations

Apo

Apolipoprotein

CRP

C-reactive protein

DAS

Disease activity score

DMARDs

Disease-modifying anti-rheumatic drugs

ESR

Erythrocyte sedimentation rate

HDL

High-density lipoprotein

IL-6

Interleukin-6

LDL

Low-density lipoprotein

RA

Rheumatoid arthritis

SAA

Serum amyloid A

TCZ

Tocilizumab

TC

Total cholesterol

TG

Triglyceride

TNF

Tumor necrosis factor

References

  1. 1.
    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46:3143–3150PubMedCrossRefGoogle Scholar
  2. 2.
    Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP et al (1998) The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128:127–137PubMedGoogle Scholar
  3. 3.
    Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G (1989) Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773–3779PubMedGoogle Scholar
  4. 4.
    Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK et al (1994) Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 14:8–13PubMedGoogle Scholar
  5. 5.
    Sun WH, Binkley N, Bidwell DW, Ershler WB (1993) The influence of recombinant human interleukin-6 on blood and immune parameters in middle-aged and old rhesus monkeys. Lymphokine Cytokine Res 12:449–455PubMedGoogle Scholar
  6. 6.
    Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B et al (2003) Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 30:1426–1435PubMedGoogle Scholar
  7. 7.
    Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRefGoogle Scholar
  8. 8.
    Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:1690–1697PubMedCrossRefGoogle Scholar
  9. 9.
    Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963PubMedCrossRefGoogle Scholar
  10. 10.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  11. 11.
    Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162–1167PubMedCrossRefGoogle Scholar
  12. 12.
    Choi HK, Seeger JD (2005) Lipid profiles among US elderly with untreated rheumatoid arthritis—the Third National Health and Nutrition Examination Survey. J Rheumatol 32:2311–2316PubMedGoogle Scholar
  13. 13.
    Mayer P, Geissler K, Valent P, Ceska M, Bettelheim P, Liehl E (1991) Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp Hematol 19:688–696PubMedGoogle Scholar
  14. 14.
    Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912PubMedCrossRefGoogle Scholar
  15. 15.
    Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T et al (2007) Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66:670–675PubMedCrossRefGoogle Scholar
  16. 16.
    Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes ES, Kastelein JJ et al (2008) Sustained changes in lipid profile and macrophage migration inhibitory factor (MIF) levels after anti-TNF therapy in rheumatoid arthritis. Ann Rheum Dis 68:1316–1321PubMedCrossRefGoogle Scholar
  17. 17.
    Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF et al (2007) Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 66:958–961PubMedCrossRefGoogle Scholar
  18. 18.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S et al (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33:2440–2446PubMedGoogle Scholar
  19. 19.
    Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M (2006) Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:414–419PubMedCrossRefGoogle Scholar
  20. 20.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497Google Scholar
  21. 21.
    Montecucco F (2009) Mach F (2007) Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 48:11–22CrossRefGoogle Scholar
  22. 22.
    Szekanecz Z, Kerekes G, Dér H, Sándor Z, Szabó Z, Végvári A et al (2007) Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 1108:349–358PubMedCrossRefGoogle Scholar
  23. 23.
    Dessein PH, Joffe BI, Singh S (2005) Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 7:R634–R643PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Shin-ya Kawashiri
    • 1
  • Atsushi Kawakami
    • 1
  • Satoshi Yamasaki
    • 1
  • Takahiro Imazato
    • 2
  • Naoki Iwamoto
    • 1
  • Keita Fujikawa
    • 1
  • Toshiyuki Aramaki
    • 1
  • Mami Tamai
    • 1
  • Hideki Nakamura
    • 1
  • Hiroaki Ida
    • 1
  • Tomoki Origuchi
    • 1
  • Yukitaka Ueki
    • 2
  • Katsumi Eguchi
    • 1
  1. 1.Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical SciencesNagasaki UniversityNagasakiJapan
  2. 2.Sasebo Chuo HospitalCenter for Rheumatic diseaseSaseboJapan

Personalised recommendations